Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

metastatic prostate cancer

  • Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    You have access
    Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Adam Hickey, Peter Eu, Martin Stockler, Andrew J. Martin, Anthony M. Joshua, Andrew Nguyen and Louise Emmett
    Journal of Nuclear Medicine February 1, 2023, 64 (2) 221-226; DOI: https://doi.org/10.2967/jnumed.122.264398
  • The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
    You have access
    The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
    Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua and Louise Emmett
    Journal of Nuclear Medicine January 1, 2023, 64 (1) 69-74; DOI: https://doi.org/10.2967/jnumed.122.264104
  • You have access
    The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy
    Lukas Lunger, Maythinee Chantadisai, Amir Karimzadeh, Isabel Rauscher, Calogero D'Alessandria, Benedikt Feuerecker, Thomas Langbein, Robert Tauber, Stefan Schiele, Wolfgang Andreas Weber and Matthias Eiber
    Journal of Nuclear Medicine December 29, 2022, jnumed.122.264962; DOI: https://doi.org/10.2967/jnumed.122.264962
  • You have access
    177Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
    Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, William Counter, Bao Ho, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Aron Poole, Adam Hickey, Shikha Agrawal, Gary Perkins, Annukka Kallinen, Enid Eslick, Martin R. Stockler, Anthony M. Joshua, Andrew Nguyen and Louise Emmett
    Journal of Nuclear Medicine September 8, 2022, jnumed.122.264677; DOI: https://doi.org/10.2967/jnumed.122.264677
  • <sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
    You have access
    177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
    Sarennya Pathmanandavel, Megan Crumbaker, Andrew O. Yam, Andrew Nguyen, Christopher Rofe, Elizabeth Hovey, Craig Gedye, Edmond M. Kwan, Christine Hauser, Arun A. Azad, Peter Eu, Andrew J. Martin, Anthony M. Joshua and Louise Emmett
    Journal of Nuclear Medicine April 1, 2022, 63 (4) 560-566; DOI: https://doi.org/10.2967/jnumed.121.262552
  • Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with <sup>18</sup>F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
    You have access
    Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
    Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven Larson, Howard I. Scher and Hebert Alberto Vargas
    Journal of Nuclear Medicine August 1, 2021, 62 (8) 1050-1056; DOI: https://doi.org/10.2967/jnumed.120.256602
  • You have access
    A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer
    Stephanie A. Harmon, Ethan Bergvall, Esther Mena, Joanna H. Shih, Stephen Adler, Yolanda McKinney, Sherif Mehralivand, Deborah E. Citrin, Anna Couvillon, Ravi A. Madan, James L. Gulley, Ronnie C. Mease, Paula M. Jacobs, Martin G. Pomper, Baris Turkbey, Peter L. Choyke and M. Liza Lindenberg
    Journal of Nuclear Medicine November 1, 2018, 59 (11) 1665-1671; DOI: https://doi.org/10.2967/jnumed.117.207373
  • You have access
    A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition
    Aseem Anand, Michael J. Morris, Reza Kaboteh, Mariana Reza, Elin Trägårdh, Naofumi Matsunaga, Lars Edenbrandt, Anders Bjartell, Steven M. Larson and David Minarik
    Journal of Nuclear Medicine December 1, 2016, 57 (12) 1865-1871; DOI: https://doi.org/10.2967/jnumed.116.177030
  • You have access
    Repeatability of Quantitative 18F-NaF PET: A Multicenter Study
    Christie Lin, Tyler Bradshaw, Timothy Perk, Stephanie Harmon, Jens Eickhoff, Ngoneh Jallow, Peter L. Choyke, William L. Dahut, Steven Larson, John Laurence Humm, Scott Perlman, Andrea B. Apolo, Michael J. Morris, Glenn Liu and Robert Jeraj
    Journal of Nuclear Medicine December 1, 2016, 57 (12) 1872-1879; DOI: https://doi.org/10.2967/jnumed.116.177295
  • You have access
    Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer
    Aseem Anand, Michael J. Morris, Reza Kaboteh, Lena Båth, May Sadik, Peter Gjertsson, Milan Lomsky, Lars Edenbrandt, David Minarik and Anders Bjartell
    Journal of Nuclear Medicine January 1, 2016, 57 (1) 41-45; DOI: https://doi.org/10.2967/jnumed.115.160085

Pages

  • Next
  • 1
  • 2
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire